Akero Looks To Accelerate Path To Pivotal NASH Data With Phase IIb/III Protocol
89Bio Builds Case For Safety Advantage As FGF Competition Heats Up
Executive Summary
Akero gets FDA’s ok to conduct Phase IIb/III study of FGF21 analog efruxifermin in biopsy-confirmed non-alcoholic steatohepatitis patients. With NASH leadership up in the air, Akero, 89bio and other FGF analog sponsors jockey for top spot.
You may also be interested in...
Akero Histology Data Could Be Best In Class For NASH
Follow-up Phase IIa data shows strong antifibrotic and NASH-resolution effects for Akero’s efruxifermin, an FGF21 analog. Analysts are calling the drug potentially best in class.
Intercept’s CRL Just Continues Upheaval In NASH
With approval timeline for OCA now thoroughly unclear and Genfit on the ropes, might the top spot in NASH end up with Galmed, AbbVie, Madrigal, Inventiva or Gilead instead?
RESOLVE-IT Failure Dashes Genfit's NASH Hopes
Genfit SA is now pinning its hopes for elafibranor on primary biliary cholangitis after the dual PPAR alpha/delta agonist failed in its Phase III RESOLVE-IT trial for NASH.
Need a specific report? 1000+ reports available
Buy Reports